ArticleFrontiers in oncology2021

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.

Jian-Zhou Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.